Novartis "buy"

07.08.06 - Jyske Bank

LONDON, August 7 (newratings.com) - Analysts at Jyske Bank maintain their "buy" rating on Novartis (NOVN).

In a research note published this morning, the analysts mention that the company's pharmaceutical division has consistently been achieving robust growth, boosted by healthy sales of its key products. Novartis is poised to launch several products in the near term, Jyske Bank adds.